The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction

Critical Care Medicine

Volumn 41, Issue 9, 2013, Pages 2080-2087

  Van Diepen, Sean ^a   Vavalle, John P ^b   Newby, L Kristin ^b   Clare, Robert ^b   Pieper, Karen S ^b   Ezekowitz, Justin A ^c   Hochman, Judith S ^c   Mahaffey, Kenneth W ^b   Armstrong, Paul W ^c   Granger, Christopher B ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

mortality; myocardial infarction; systemic inflammatory response syndrome

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEXELIZUMAB; PLACEBO; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; BREATHING; BREATHING RATE; CARDIOGENIC SHOCK; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HAZARD RATIO; HEART DEATH; HEART FAILURE; HEART RATE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MECHANICAL REPERFUSION; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; CANADA; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); SHOCK, CARDIOGENIC; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNITED STATES;

EID: 84883657695     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31828a67b2     Document Type: Article

References (39)

1. Talmor M, Hydo L, Barie PS: Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: Effect of intensive care unit resuscitation. Arch Surg 1999; 134:81-87
2. Rolando N, Wade J, Davalos M, et al: The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32(4 Part 1):734-739
3. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
4. Rangel-Frausto MS, Pittet D, Costigan M, et al: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123
5. Napolitano LM, Ferrer T, McCarter RJ Jr, et al: Systemic inflammatory response syndrome score at admission independently predicts mortality and length of stay in trauma patients. J Trauma 2000; 49:647-652
6. Frangogiannis NG, Mendoza LH, Lewallen M, et al: Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J 2001; 15:1428-1430
7. Nian M, Lee P, Khaper N, et al: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004; 94:1543-1553
8. Fosco MJ, Ceretti V, Agranatti D: Systemic inflammatory response syndrome predicts mortality in acute coronary syndrome without congestive heart failure. West J Emerg Med 2010; 11:373-378
9. Samimi-Fard S, Dominguez-Rodriguez A, Abreu-Gonzalez P, et al: Role of myeloperoxidase as predictor of systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention. Am J Cardiol 2009; 104:634-637
10. García González MJ, Domínguez Rodríguez A, Santacreu Iniesta R, et al: Systemic inflammatory response syndrome: Prevalence and influence on outcome in acute myocardial infarction treated with primary angioplasty. Med Intensiva 2007; 31:289-293
11. Granger CB, Mahaffey KW, Weaver WD, et al; COMMA Investigators: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108:1184-1190
12. Mahaffey KW, Granger CB, Nicolau JC, et al; COMPLY Investigators: Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thrombo-LYtics (COMPLY) trial. Circulation 2003; 108:1176-1183
13. The APEX-AMI Investigators: Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. JAMA 2007; 297:43-51
14. Bone RC: Let's agree on terminology: Definitions of sepsis. Crit Care Med 1991; 19:973-976
15. Bone RC: Sepsis, the sepsis syndrome, multi-organ failure: A plea for comparable definitions. Ann Intern Med 1991; 114:332-333
16. Bown MJ, Nicholson ML, Bell PR, et al: The systemic inflammatory response syndrome, organ failure, and mortality after abdominal aortic aneurysm repair. J Vasc Surg 2003; 37:600-606
17. Alam SE, Nasser SS, Fernainy KE, et al: Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 2004; 4:166-170
18. Pannitteri G, Marino B, Campa PP, et al: Interleukins 6 and 8 as mediators of acute phase response in acute myocardial infarction. Am J Cardiol 1997; 80:622-625
19. Tan J, Hua Q, Gao J, et al: Clinical implications of elevated serum interleukin-6, soluble CD40 ligand, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in patients with acute ST-segment elevation myocardial infarction. Clin Cardiol 2008; 31:413-418
20. Ridker PM, Rifai N, Pfeffer M, et al: Elevation of tumor necrosis factoralpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-2153
21. Pasqui AL, Di Renzo M, Bova G, et al: Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med 2006; 6:38-44
22. Cremer J, Martin M, Redl H, et al: Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61:1714-1720
23. Kohsaka S, Menon V, Lowe AM, et al; SHOCK Investigators: Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock. Arch Intern Med 2005; 165:1643-1650
24. Sinning JM, Scheer AC, Adenauer V, et al: Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation. Eur Heart J 2012; 33:1459-1468
25. Granger CB, Goldberg RJ, Dabbous O, et al; Global Registry of Acute Coronary Events Investigators: Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163:2345-2353
26. Stebbins A, Mehta RH, Armstrong PW, et al; Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI Investigators): A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: Results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv 2010; 3:414-422
27. Normand SLT, Glickman ME, Sharma RGVRK, et al: Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. JAMA 1996; 275:1322-1328
28. Patel MR, Mahaffey KW, Armstrong PW, et al; CARDINAL Investigators: Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol 2005; 95:614-618
29. Ben-Dor I, Haim M, Rechavia E, et al: Body temperature-a marker of infarct size in the era of early reperfusion. Cardiology 2005; 103:169-173
30. Gheorghiade M, Zannad F, Sopko G, et al; International Working Group on Acute Heart Failure Syndromes: Acute heart failure syndromes: Current state and framework for future research. Circulation 2005; 112:3958-3968
31. Lemeshow S, Teres D, Avrunin JS, et al: Refining intensive care unit outcome prediction by using changing probabilities of mortality. Crit Care Med 1988; 16:470-477
32. Chang WC, Boersma E, Granger CB, et al; GUSTO-IIb and PURSUIT Investigators: Dynamic prognostication in non-ST-elevation acute coronary syndromes: Insights from GUSTO-IIb and PURSUIT. Am Heart J 2004; 148:62-71
33. Kilic T, Ural D, Ural E, et al: Relation between proinflammatory to antiinflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart 2006; 92:1041-1046
34. Lee KW, Lip GY, Tayebjee M, et al: Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105:526-532
35. Smith DA, Irving SD, Sheldon J, et al: Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104:746-749
36. Théroux P, Armstrong PW, Mahaffey KW, et al: Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: A substudy of the COMMA trial. Eur Heart J 2005; 26:1964-1970
37. Vasan RS, Sullivan LM, Roubenoff R, et al; Framingham Heart Study: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation 2003; 107:1486-1491
38. Maeda K, Tsutamoto T, Wada A, et al: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36:1587-1593
39. Truffa AA, Granger CB, White KR, et al: Serious infection after acute myocardial infarction: Prevalence, clinical features, and outcomes. JACC Cardiovasc Interv 2012; 5:769-776